Search
for
Sort by
Research 30 of 103
- Baricitinib (Olumiant)
- Baricitinib (Olumiant)
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Shedding light on therapeutics in alopecia and their relevance to COVID-19
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- European expert consensus statement on the systemic treatment of alopecia areata
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Baricitinib as the first systemic treatment for severe alopecia areata
- Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
- Alopecia areata: from pathophysiology to therapeutic innovation
- Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment
- Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
- 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
- Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
- Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
- Drug pipeline 2Q22 — a downturn in approvals
- Lilly arthritis drug approved for alopecia
- SnapshotDx Quiz: March 2016
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Update: baricitinib for alopecia areata
- New drugs under investigation for the treatment of alopecias
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- Methods of Using of Cosmeceuticals in Trichological Practice
- Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis